JP4468578B2 - Ｉｌ−６アンタゴニストペプチド - Google Patents

Ｉｌ−６アンタゴニストペプチド Download PDF

Info

Publication number
JP4468578B2
JP4468578B2 JP2000549631A JP2000549631A JP4468578B2 JP 4468578 B2 JP4468578 B2 JP 4468578B2 JP 2000549631 A JP2000549631 A JP 2000549631A JP 2000549631 A JP2000549631 A JP 2000549631A JP 4468578 B2 JP4468578 B2 JP 4468578B2
Authority
JP
Japan
Prior art keywords
seq
peptide
protein
domain
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000549631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527354A (ja
JP2002527354A5 (enExample
Inventor
セルルピ−クレスチェンツィ，オッタビアーノ
ブレッサン，アレッサンドロ
ピエトラ，リンダ デッラ
リタ ペツォッティ，アンナ
Original Assignee
メルク セローノ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク セローノ ソシエテ アノニム filed Critical メルク セローノ ソシエテ アノニム
Publication of JP2002527354A publication Critical patent/JP2002527354A/ja
Publication of JP2002527354A5 publication Critical patent/JP2002527354A5/ja
Application granted granted Critical
Publication of JP4468578B2 publication Critical patent/JP4468578B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000549631A 1998-05-18 1999-05-18 Ｉｌ−６アンタゴニストペプチド Expired - Fee Related JP4468578B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98108997.2 1998-05-18
EP98108997A EP0972780A1 (en) 1998-05-18 1998-05-18 Il-6 antagonist peptides
PCT/EP1999/003421 WO1999060013A2 (en) 1998-05-18 1999-05-18 Il-6 antagonist peptides

Publications (3)

Publication Number Publication Date
JP2002527354A JP2002527354A (ja) 2002-08-27
JP2002527354A5 JP2002527354A5 (enExample) 2006-05-18
JP4468578B2 true JP4468578B2 (ja) 2010-05-26

Family

ID=8231951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000549631A Expired - Fee Related JP4468578B2 (ja) 1998-05-18 1999-05-18 Ｉｌ−６アンタゴニストペプチド

Country Status (14)

Country Link
US (2) US6599875B1 (enExample)
EP (2) EP0972780A1 (enExample)
JP (1) JP4468578B2 (enExample)
AT (1) ATE347563T1 (enExample)
AU (1) AU749616B2 (enExample)
CA (2) CA2690399C (enExample)
CY (1) CY1105865T1 (enExample)
DE (1) DE69934308T2 (enExample)
DK (1) DK1078001T3 (enExample)
ES (1) ES2273492T3 (enExample)
IL (2) IL139575A0 (enExample)
PT (1) PT1078001E (enExample)
SI (1) SI1078001T1 (enExample)
WO (1) WO1999060013A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US12509511B2 (en) 2017-05-02 2025-12-30 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972780A1 (en) * 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
DK1783222T3 (da) 1998-10-23 2012-07-09 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
US20070036788A1 (en) * 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
MX2007003320A (es) 2004-09-24 2007-05-18 Amgen Inc Moleculas fc modificadas.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
ES2564392T3 (es) 2007-01-23 2016-03-22 Shinshu University Inhibidores de IL-6 para el tratamiento de rechazo crónico
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
KR20110112307A (ko) 2008-11-25 2011-10-12 앨더 바이오파마슈티컬즈, 인코포레이티드 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ­６의 길항제
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
ES2778053T3 (es) * 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CN103923182A (zh) * 2014-01-17 2014-07-16 南通诚信氨基酸有限公司 白介素-6多肽抑制剂及其应用
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-ｃ-사이토카인 활성의 조정
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US12030936B2 (en) 2019-05-03 2024-07-09 Bioniz Therapeutics, Inc. Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
CN116003530B (zh) * 2022-12-27 2023-12-15 西湖大学 一种针对白细胞介素-6的d-蛋白抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420782C1 (de) * 1994-06-15 1995-08-17 Fluegge Ulf Ingo Prof Dr DNA-Sequenz, kodierend einen 2-Oxoglutarat/Malat-Translokator, Plasmide, Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
JPH10506463A (ja) * 1994-09-21 1998-06-23 サイトーゲン コーポレーション ペプチドライブラリー由来の抗原結合性ペプチド（アブチド）
WO1996023899A1 (en) * 1995-02-01 1996-08-08 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
US6004813A (en) * 1995-05-11 1999-12-21 Applied Research Systems Ars Holding N.V. Il-6 activity inhibitor
AU6731896A (en) * 1995-07-17 1997-02-18 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Cyclitol
WO1997013781A2 (en) * 1995-09-28 1997-04-17 Yeda Research And Development Co. Ltd. Synthetic peptides that inhibit il-6 activity
WO1997048728A1 (en) * 1996-06-20 1997-12-24 Koster, Henk, Wilhelmus Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity
EP0972780A1 (en) * 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US12509511B2 (en) 2017-05-02 2025-12-30 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Also Published As

Publication number Publication date
US6838433B2 (en) 2005-01-04
EP1078001B1 (en) 2006-12-06
DK1078001T3 (da) 2007-02-19
CY1105865T1 (el) 2011-02-02
IL139575A (en) 2008-03-20
CA2690399C (en) 2015-01-20
JP2002527354A (ja) 2002-08-27
WO1999060013A3 (en) 2000-03-09
DE69934308T2 (de) 2007-03-29
CA2690399A1 (en) 1999-11-25
US6599875B1 (en) 2003-07-29
CA2332817C (en) 2010-08-31
EP1078001A2 (en) 2001-02-28
IL139575A0 (en) 2002-02-10
PT1078001E (pt) 2007-01-31
AU4362799A (en) 1999-12-06
CA2332817A1 (en) 1999-11-25
US20030186876A1 (en) 2003-10-02
DE69934308D1 (de) 2007-01-18
EP0972780A1 (en) 2000-01-19
ATE347563T1 (de) 2006-12-15
AU749616B2 (en) 2002-06-27
WO1999060013A2 (en) 1999-11-25
ES2273492T3 (es) 2007-05-01
SI1078001T1 (sl) 2007-04-30

Similar Documents

Publication Publication Date Title
JP4468578B2 (ja) Ｉｌ−６アンタゴニストペプチド
US5525486A (en) Process for constructing cDNA library, and novel polypeptide and DNA coding for the same
JP3367581B2 (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US5880096A (en) Peptides and compounds that bind to the IL-1 receptor
US5863769A (en) DNA encoding interleukin-1 receptor antagonist (IL-1raβ)
US5786331A (en) Peptides and compounds that bind to the IL-1 receptor
AU732793B2 (en) Modulators of TNF receptor associated factor (TRAF), their preparation and use
WO1999054357A1 (en) Novel cytokine-like protein
JPH10508742A (ja) ヒトケモカインポリペプチド
JPH10511266A (ja) ヒト・インターロイキン−１１受容体
US5861476A (en) Peptides and compounds that bind to the IL-1 receptor
KR100270348B1 (ko) 전사인자 에이피알에프
JP2000083688A (ja) ＩＬ―１ファミリ―の新規メンバ―、ＩＬ―１δ
JPH10506538A (ja) Ｇｐ１３０に全く結合することができないヒトインターロイキン−６の拮抗薬、および医薬化合物の製造におけるそれらの使用
AU711573B2 (en) Short forms of chemokine beta-8
US6121237A (en) Neutrophil stimulating peptides
CA2216147A1 (en) Cellubrevin homologs
US6342371B1 (en) Interleukin-1 homologue, IL-1H4
WO1999065450A2 (en) Immunosuppressive agents that inhibit calcineurin function and uses thereof
US20030138400A1 (en) Short forms of chemokine beta-8
US20020165350A1 (en) Novel polypeptide, a method of producing it, and utility of the polypeptide
JPWO1999054357A1 (ja) 新規なサイトカイン様タンパク質
WO2001027148A1 (fr) Nouveau polypeptide, facteur homo 56 riche en glutamine(q), et polynucleotide codant pour ce polypeptide
AU3508101A (en) Modulators of TNF receptor associated factor (TRAF), their preparation and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060317

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100225

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130305

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130305

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140305

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees